News for Viatris Inc. (VTRS)

PR NewswireSAN DIEGO, July 23, 2025 DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technologyApproval represents critical advan

PR NewswireDUBLIN, July 23, 2025 DUBLIN, July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

PR NewswireSAN DIEGO, July 22, 2025 SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it wil

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain offic

Key Highlights: Viatris (VTRS) shares experienced a premarket drop due to the failure of their blepharitis treatment in a late-stage trial. Analysts offe

Viatris (VTRS) revealed that its Phase 3 trial, which investigated the effectiveness and safety of pimecrolimus 0.3% ophthalmic ointment for blepharitis, did no

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified for VTRS stock.

Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD. Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for […]

Viatris Inc. (NASDAQ:VTRS) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on June 30, Goldman Sachs reiterated a Hold rating on Viatris Inc. (NASDAQ:VTRS) with a price target of $10.00. The company reported $3.3 billion in total revenues in fiscal Q1 2025, down 11% on a reported basis and […]

J&J(JNJ) wins U.S. appeals court case protecting its Invega Sustenna patent from generic rivals Viatris (VTRS) & Teva (TEVA). Read more here.

Viatris faces downside risk from regulatory challenges, macro headwinds, and muted growth. Click to learn more on why VTRS may be a value trap.

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

PR NewswireSAN DIEGO, June 20, 2025 SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver,

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Via

Viatris Inc. (NASDAQ:VTRS) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ParticipantsCorinne M.

In the latest analyst move, Goldman Sachs has initiated coverage on Viatris, Inc. (VTRS), providing investors with an updated outlook on the stock. The coverage

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Theravance Biopharma and Mylan settle a patent dispute with Eugia Pharma over Yupelri, delaying generic entry until 2039. Read more here.